Stribild

Antiretroviral Therapy, HIV test negative, HIV Infections + 12 more
Treatment
2 FDA approvals
20 Active Studies for Stribild

What is Stribild

EmtricitabineThe Generic name of this drug
Treatment SummaryCobicistat (brand name Tybost or formerly GS-9350) is a medication used to help treat HIV. It does not directly fight HIV, but it helps increase the effects of other medications used to treat HIV by blocking certain enzymes in the body. It is most commonly used to increase the effectiveness of atazanavir or darunavir, two anti-retroviral medications used to treat HIV. By increasing the effects of these medications without increasing the dosage, cobicistat can help improve treatment outcomes and reduce side effects.
Emtrivais the brand name
Stribild Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Emtriva
Emtricitabine
2003
131

Approved as Treatment by the FDA

Emtricitabine, also called Emtriva, is approved by the FDA for 2 uses including HIV and adults and pediatric patients weighing at least 17 kg .
HIV
Helps manage Human Immunodeficiency Virus Type 1 (HIV-1) Infection
adults and pediatric patients weighing at least 17 kg

Effectiveness

How Stribild works in the bodyCobicistat helps increase the effectiveness of certain HIV medications by blocking the enzymes that break them down. This allows the medications to stay in the body longer, resulting in improved anti-viral activity. Cobicistat is not an anti-HIV drug itself and does not provide any direct benefits.

When to interrupt dosage

The proposed dosage of Stribild is contingent upon the ascertained condition. The measure of dosage is dependent on the technique of administration, which can be found in the table below.
Condition
Dosage
Administration
Antiretroviral Therapy
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
HIV test negative
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
HIV Infections
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
HIV Transmission
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
Anti-Retroviral Agents
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
adults and pediatric patients weighing at least 17 kg
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
not requiring CYP3A inhibitors
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
treatment failure
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution
Sexual Behavior
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution - Oral, Solution

Warnings

Stribild Contraindications
Condition
Risk Level
Notes
HIV
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Emtricitabine may interact with Pulse Frequency
There are 20 known major drug interactions with Stribild.
Common Stribild Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Emtricitabine.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Emtricitabine.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Emtricitabine.
Cefradine
Minor
The excretion of Cefradine can be decreased when combined with Emtricitabine.
Estrone sulfate
Minor
The excretion of Estrone sulfate can be decreased when combined with Emtricitabine.
Stribild Toxicity & Overdose RiskCommon side effects of this drug include yellowing of the skin or eyes (jaundice), yellowing of the eyes (icterus), and feeling sick to the stomach (nausea).

Stribild Novel Uses: Which Conditions Have a Clinical Trial Featuring Stribild?

165 clinical trials are presently assessing the potential of Stribild in providing relief from HIV and related conditions.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Sexual Behavior
10 Actively Recruiting
Not Applicable, Phase 4
HIV Infections
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting
treatment failure
0 Actively Recruiting
adults and pediatric patients weighing at least 17 kg
0 Actively Recruiting
HIV Transmission
0 Actively Recruiting
Obesity
0 Actively Recruiting
Antiretroviral Therapy
0 Actively Recruiting
HIV
0 Actively Recruiting
Obesity
0 Actively Recruiting
not requiring CYP3A inhibitors
0 Actively Recruiting
HIV test negative
0 Actively Recruiting
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Obesity
0 Actively Recruiting

Stribild Reviews: What are patients saying about Stribild?

5Patient Review
4/21/2014
Stribild for HIV
5Patient Review
10/15/2015
Stribild for HIV
Since beginning treatment with strbilid and dapsone, I have seen a significant decrease in my viral load. My energy levels have also increased, and I no longer feel the need to take naps during the day. I am hopeful that this trend will continue and that I will eventually achieve undetectability.
5Patient Review
9/27/2014
Stribild for HIV
This new pill has really changed my life for the better. I'm so glad I decided to ask my doctor about it.
5Patient Review
6/9/2014
Stribild for HIV
I'm always a bit hesitant about trying new medications, and this one is no exception. That said, it has really helped me in ways that other treatments haven't. I don't have to worry about food restrictions, which is great.
5Patient Review
11/15/2015
Stribild for HIV
I was only taking medication while pregnant, but now that I'm done having kids the HIV was slowly coming back. In just three weeks of taking stribild, my levels went from 9000 to undetectable. There were no side effects in the beginning, but now (4 weeks after my first dose) I've been getting vertigo and headaches more often than not in the evenings.
5Patient Review
8/8/2015
Stribild for HIV
I was diagnosed with HIV in June 2014 and had no idea what to expect. I started this treatment on July 10 and felt a lot better almost immediately. Suddenly, the symptoms of HIV became much clearer. The rash was clearing up and when I went to the doctor on July 29, most of the symptoms had cleared greatly. This drug is amazing!
5Patient Review
8/16/2016
Stribild for HIV
After four weeks of treatment, my VL (viral load) went from 56,000 to just 85! My CD4 (cluster of differentiation 4) count went from 151 to 207. I felt hungover and experienced some anxiety and insomnia the first two weeks; however, I have had zero issues taking it since then. Additionally, I supplement with vitamin D and Selenium. Gilead's copay card covered this medication entirely for me.
5Patient Review
10/30/2014
Stribild for HIV
I was diagnosed in March/April of 2014 and started taking Stribild. Within two weeks, my CD4 had risen to 204 and my VL 5-days into meds dropped to 4,000. I just had my 6 month check up today and my VL is >1 and CD4 is at 298. I've experienced no side effects after some minor things the first 2 weeks (my body healing). I take one every morning and it has made this process much easier to deal with and manage.
4.7Patient Review
7/29/2014
Stribild for HIV
This drug has been great in boosting my CD4 levels, but unfortunately I've developed psoriasis since starting it.
4.7Patient Review
11/21/2015
Stribild for HIV
The dizziness and headaches are unfortunate side effects, but they haven't been bad enough to outweigh the positives of this medication. I'll be contacting my doctor to see what can be done about them, though.
4.3Patient Review
7/12/2014
Stribild for HIV
I've been taking this medication for two years with no negative side effects. It's only once a day, which is really convenient, and it's lowered my viral load to undetectable levels.
4.3Patient Review
4/23/2014
Stribild for HIV
Quick-acting and easy to use, this medication was great with minimal side effects.
4Patient Review
1/11/2016
Stribild for HIV
I had to stop taking this after thirty days when my liver enzymes started spiking. My doctor said it wasn't uncommon, but that if I didn't get off the medication it could cause serious damage. He switched me to Genvoya, which is similar but with less of the ingredient that can cause problems. So far so good!
3.7Patient Review
12/27/2016
Stribild for HIV
I started taking Stribild for my HIV treatment, and it's been absolutely awful. I feel hungover and achy all the time. I'm going back to Atripla tomorrow.
3Patient Review
12/17/2015
Stribild for HIV
I started this treatment two weeks ago and immediately felt pain in my left arm, as well as some headaches and blurred vision. Recently, I've also had acid reflux for the past three days.
1.7Patient Review
9/7/2015
Stribild for HIV
I've been on Sribild for almost three weeks now and have had nothing but terrible side effects like nausea and stomach cramps. I would not recommend this medication to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about stribild

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Stribild cause weight gain?

"Weight gain is not a common side effect for those taking Stribild, however, a recent study shows that some of the newer HIV treatments that contain integrase strand inhibitors like elvitegravir (which is found in Stribild) can be linked to significant weight gain."

Answered by AI

What are the side effects of Stribild?

"You may experience diarrhea, headache, dizziness, trouble sleeping, unusual dreams, back pain, or a change in the color of skin on your palms or soles of your feet. If you experience any of these effects for an extended period of time, or if they get worse, please notify your doctor or pharmacist."

Answered by AI

What is the drug Stribild used for?

"STRIBILD is a prescription medicine that is used to treat Human Immunodeficiency Virus-1 (HIV-1) in people 12 years of age and older, who have not received anti-HIV-1 medicines in the past, or to replace their current anti-HIV-1 medicines: in people who have been on the same anti-HIV-1 medicine regimen for at least 6 months, and who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL)."

Answered by AI

What diagnosis is Stribild?

"Stribild is a medication used to treat HIV. It is prescribed for adults and children ages 12 years and older who weigh at least 35 kilograms (about 77 pounds). Stribild does not need to be taken with other HIV medications."

Answered by AI

Clinical Trials for Stribild

Image of Neighborhood Healthcare in Escondido, United States.

Cagrilintide + CagriSema for Childhood Obesity

8 - 18
All Sexes
Escondido, CA
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.
Phase 3
Waitlist Available
Neighborhood Healthcare (+30 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S
Have you considered Stribild clinical trials? We made a collection of clinical trials featuring Stribild, we think they might fit your search criteria.Go to Trials
Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Waitlist Available
Has No Placebo
UConn Health (+2 Sites)Linda S Pescatello, PhD
Have you considered Stribild clinical trials? We made a collection of clinical trials featuring Stribild, we think they might fit your search criteria.Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Have you considered Stribild clinical trials? We made a collection of clinical trials featuring Stribild, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security